KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) EPS (Weighted Average and Diluted) (2018 - 2026)

NovoCure recorded quarterly EPS (Weighted Average and Diluted) of -$0.62 in Q1 2026, down 181.82% quarter-over-quarter from -$0.22 in Q4 2025, and down 100.0% year-over-year from -$inf billion in Q1 2025.

NovoCure's EPS (Weighted Average and Diluted) history runs 9 years deep, the most recent figure standing at -$0.62 for Q1 2026.

  • In Q1 2026, EPS (Weighted Average and Diluted) fell 100.0% year-over-year to -$0.62; the TTM figure through Mar 2026 stood at -$1.53 (down 1.32% YoY), while the FY2025 annual figure was -$1.22, up 21.79% from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.62 for Q1 2026 at NovoCure, down from -$0.22 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.04 in Q1 2022 to a low of -$0.62 in Q1 2026.
  • A 5-year average of -$0.37 and a median of -$0.36 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
  • Across the five-year window, EPS (Weighted Average and Diluted) plunged 1150.0% in 2023 and soared 63.93% in 2025, its largest moves.
  • NovoCure's EPS (Weighted Average and Diluted) stood at -$0.36 in 2022, then fell by 22.22% to -$0.44 in 2023, then sank by 38.64% to -$0.61 in 2024, then soared by 63.93% to -$0.22 in 2025, then sank by 181.82% to -$0.62 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.62, -$0.22, and -$0.33 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.61
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.93
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.89
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.90
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.66
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.51
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.85
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 2.24
10 NovoCure 1.90 Bn 1.47 Bn 135.13 Mn -0.62

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.62
Dec 31, 2025 -0.22
Sep 30, 2025 -0.33
Jun 30, 2025 -0.36
Mar 31, 2025 -0.31
Dec 31, 2024 -0.61
Sep 30, 2024 -0.28
Jun 30, 2024 -0.31
Mar 31, 2024 -0.36
Dec 31, 2023 -0.44
Sep 30, 2023 -0.46
Jun 30, 2023 -0.54
Mar 31, 2023 -0.50
Dec 31, 2022 -0.36
Sep 30, 2022 -0.25
Jun 30, 2022 -0.23
Mar 31, 2022 -0.04
Dec 31, 2021 -0.25
Sep 30, 2021 -0.13
Jun 30, 2021 -0.14
Mar 31, 2021 -0.04
Dec 31, 2020 0.04
Sep 30, 2020 0.09
Jun 30, 2020 0.02
Mar 31, 2020 0.04
Dec 31, 2019 0.04
Sep 30, 2019 0.02
Jun 30, 2019 -0.01
Mar 31, 2019 -0.13
Dec 31, 2018 -0.17
Sep 30, 2018 -0.13